8R-70CAR T-cells

8R-70CAR T-cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target the CD70 protein, which is overexpressed in various hematologic and solid tumors. These T-cells are uniquely modified to constitutively express CXCR2 (the IL-8 receptor), a modification intended to enhance the cells' ability to migrate toward IL-8-rich tumor microenvironments, such as those found in glioblastoma and acute myeloid leukemia (AML). This "8R" modification aims to overcome common CAR-T limitations like poor trafficking and fitness by harnessing cytokine gradients. The therapy is currently being evaluated in Phase I clinical trials for glioblastoma and is undergoing preclinical investigation for AML, where it may be used in combination with epigenetic modifiers like azacitidine to increase target density.

Other names

CD70 CXCR2-Modified CAR T-CellsCD-70 CXCR2-Modified CAR T-CellsCD 70 CXCR2-Modified CAR T-CellsCXCR2-modified CD70 CAR T-cellsCXCR-2-modified CD70 CAR T-cellsCXCR 2-modified CD70 CAR T-cells